SEARCH

SEARCH BY CITATION

References

  • 1
    Talley NJ, Stanghellinin V, Heading RC, Koch KL, Malageleda JR, Tytgat GNJ. Functional gastroduodenal disorders. Gut 1999; 45(Suppl. II): 113742.
  • 2
    Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45(Suppl. II): 116977.
  • 3
    Veldhuyzen van Zanten SJ, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ 2000; 162(12 Suppl.): S323.
  • 4
    Moayyedi P, Feltbower R, Brown J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. Lancet 2000; 355(9216): 16659.
  • 5
    Hansen JM, Bytzer P, Schaffalitzky de Muckadell OB. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. Am J Gastroenterol 1998; 93(3): 36874.
    Direct Link:
  • 6
    Chen JD, Ke MY, Lin XM, Wang Z, Zhang M. Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality. Aliment Pharmacol Ther 2000; 14(8): 10417.
  • 7
    Holtmann G, Schossman J, Mayr P, Talley NJ. A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Aliment Pharmacol Ther 2002; 16(9): 16418.
  • 8
    Bekhti A, Rutgeerts L. Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying. Postgrad Med J 1979; 55(Suppl. 1): 302.
  • 9
    Van Outryve M, De Nutte N, Van Eeghem P, Gooris JP. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study. Scand J Gastroenterol Suppl 1993; 195: 4752; discussion 52–3.
  • 10
    Talley NJ, Meinech-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12(11): 105565.
  • 11
    Wong WM, Wong BCY, Hung WK, et al. Double blind, randomized, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002; 51: 5026.
  • 12
    McColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998; 339(26): 186974.
  • 13
    Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998; 339(26): 187581.
  • 14
    Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Br Med J 1999; 318(7187): 8337.
  • 15
    Talley NJ, Vakil N, Ballard ED 2nd, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. N Engl J Med 1999; 7(34): 110611.
  • 16
    Froehlich F, Gonvers JJ, Wietlisbach V, et al. Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. Am J Gastroenterol 2001; 96(8): 232936.
    Direct Link:
  • 17
    Hamilton J, Guthrie E, Creed F, et al. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000; 119(3): 6619.
  • 18
    Calvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002; 123: 177885.
  • 19
    Finney JS, Kinnersley N, Hughes M, O'Bryan-Tear CG, Lothian J. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998; 26: 31220.
  • 20
    Dobrilla G, Comberlato M, Steele A, Vallaperta P. Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol 1989; 11: 16977.
  • 21
    Redstone HA, Barrowman N, Veldhuyzen van Zanten SJO. H2-receptor antagonists in the treatment of functional (non-ulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 2001; 15: 12919.
  • 22
    Bytzer P. H2 receptor antagonists and prokinetics in dyspepsia: a critical review. Gut 2002; 50(Suppl. 4): iv: 58–62.
  • 23
    Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 68996.
  • 24
    Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2000; 2: CD01960.
  • 25
    Moher D, Jones A, Cook DJ, et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 60913.
  • 26
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 112.
  • 27
    Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2001; 1: CD002096.
  • 28
    Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 134(5): 3619.
  • 29
    Veldhuzyzen van Zanten SJO, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996; 91(4): 66073.
  • 30
    Section 8.4.4 Fixed effect versus random effects analysis. Cochrane Reviewers' Handbook. Available at http://www.cochrane.de/cochrane/hbook.htm; v.4.1.6, January 2003.
  • 31
    Delattre M, Malesky M, Prinzie A. Symptomatic treatment of non-ulcer dyspepsia with cimetidine. Curr Ther Res 1985; 37(5): 98091.
  • 32
    Gotthard R, Bodemar G, Brodin U, Jonsson KA. Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988; 23(1): 718.
  • 33
    Hadi S. Clinical investigation of ranitidine in patients with gastritis. Clin Ther 1989; 11(5): 5904.
  • 34
    Kelbaek H, Linde J, Eriksen J, Mungaard S, Moesgaard F, Bonnevie O. Controlled clinical trial of treatment with cimetidine for non-ulcer dyspepsia. Acta Med Scand 1985; 217(3): 2817.
  • 35
    Mackinnon M, Willing RL, Whitehead R. Cimetidine in the management of symptomatic patients with duodenitis: a double-blind controlled trial. Dig Dis Sci 1982; 27(3): 2179.
  • 36
    Muller P, Hotz J, Franz E, Simon B. Ranitidine in the treatment of non-ulcer dyspepsia. A placebo-controlled study in the Federal Republic of Germany. Arzneim-Forsch/Drug Res 1994; 10: 11302.
  • 37
    Nesland AA, Berstad A. Effect of cimetidine in patients with non-ulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol 1985; 20(5): 62935.
  • 38
    Olubuyide OA, Atoba MA. Non-ulcer dyspepsia in Nigerians: clinical and therapeutic results. Scand J Gastroenterol 1986; 21(Suppl. 124): 837.
  • 39
    Singal AK, Kumar A, Broor SL. Cimetidine in the treatment of non-ulcer dyspepsia: results of a randomized double-blind, placebo-controlled study. Curr Med Res Opin 1989; 11(6): 3907.
  • 40
    Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. Gut 2000; 47: 47380.
  • 41
    Saunders JH, Oliver RJ, Higson DL. Dyspepsia: incidence of a non-ulcer disease in a controlled trial of ranitidine in general practice. Br Med J Clin Res Ed 1994; 1986(6521): 6658.
  • 42
    Al-Quorain A, Larbi EB, Al-Shedoki F. A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia. Scand J Gastroenterol 1995; 30(6): 5314.
  • 43
    Champion MC, MacCannell KL, Thomson ABR, et al. A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. Can J Gastroenterol 1997; 11(2): 12734.
  • 44
    Chung JM. Cisapride in chronic dyspepsia: results of a double-blind, placebo controlled trial. Scand J Gastroenterol 1993; 195(Suppl.): 114.
  • 45
    De Groot GH, De Both PSM. Cisapride in functional dyspepsia in general practice. A placebo controlled, randomized double blind study. Aliment Pharmacol Ther 1997; 11: 1939.
  • 46
    De Nutte N, Van Ganse W, Witterhulghe M, Defrance P. Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride. Clin Ther 1989; 11(1): 628.
  • 47
    Francois I, De Nutte N. Nonulcer dyspepsia: effect of the gastrointestinal prokinetic drug cisapride. Curr Ther Res 1987; 41(6): 8918.
  • 48
    Hannon R. Efficacy of cisapride in patients with nonulcer dyspepsia. A placebo-controlled study. Curr Ther Res 1987; 42(5): 81422.
  • 49
    Kellow JE, Cowan H, Shuter B, et al. Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther 1995; 9(2): 15360.
  • 50
    Rosch W. Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial. Scand J Gastroenterol 1987; 22(2): 1614.
  • 51
    Wood SF, Penney SC, Cochran KM. Cisapride in functional dyspepsia: a double-blind, placebo-controlled randomized trial in general practice patients. Scand J Gastroenterol 1993; 28(Suppl. 195): 510.
  • 52
    Yeoh KG, Kang JY, Tay HH, et al. Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double-blind placebo-controlled trial. J Gastroenterol Hepatol 1997; 12(1): 138.
  • 53
    Bruley des Varannes S, Flejou JF, Colin R, Zaim M, Meunier A, Bidaut-Mazel C. There are some benefits for eradicating Helicobacter pylori in patients with non ulcer dyspepsia. Aliment Pharmacol Ther 2001; 15: 117785.
  • 54
    Gisbert JP, Cruzado AL, Garcia-Gravalos R, Pajares JM. Lack of benefit of treating Helicobacter pylori infection in patients with functional dyspepsia. Randomized one-year follow-up study. Hepato-gastroenterology 2003 in press .
  • 55
    Hsu PL, Lai KH, Tseng HH, et al. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 195201.
  • 56
    Koskenpato J, Farkkila M, Sipponen P. Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia. Am J Gastroenterol 2001; 96: 286672.
    Direct Link:
  • 57
    Miwa H, Hirai S, Nagahara A, et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients — a double-blind placebo-controlled study. Aliment Pharmacol Ther 2000; 14: 31724.
  • 58
    Koelz HR, Arnold R, Stolte M, Fischer M, Blum AL, the FROSCH Study Group. Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomized trial with a six month follow up. Gut 2003; 52: 406.
  • 59
    McColl KE, El-Nujumi A, Murray L, et al. The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients. Gut 1998; 40(3): 3026.
  • 60
    Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. J Am Med Assoc 1995; 273: 40812.
  • 61
    Wong WM, Lam SK, Hui WM, et al. Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese — prevalence and spectrum of the disease. Aliment Pharmacol Ther 2002; 16: 203742.